JPRN-UMIN000013597招募中未知
The randomized trial of Peginterferon alfa 2a or alfa2b with simeprevir and ribavirin for chronic hepatitis C - The randomized trial of Peginterferon alfa 2a or alfa2b with simeprevir and ribavirin for chronic hepatitis C
Graduate School of Medical Sciences, Kumamoto University, Department of Gastroenterology and Hepatology0 个研究点目标入组 140 人开始时间: 2014年4月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.pregnancy or breast feeding female severe allergy to IFN 2, 3.severe allergy to RBV or nucreosid analogue 4.uncontrolled cardiac diseases 5.Hemoglobinopathies 6.chronic renal failure or less than 50 ml /min of CCr 7.severe psychiatric disorder 8.severe cirrhotic patients 9.The history of interstitial pneumonitis 10.Autoimmune hepatitis 11.The history of the allergy to biochemical agents 12.receiving disallowed drugs 13.uncontrolled diabetes mellitus 14.patients with HCC(except for curative patients) 15.co-infection of HBV and/or HIV 16.patients who not permit the participate this study
研究者
相似试验
进行中（未招募）
不适用
Trial to compare the responses in two strata of patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia. Each patient will receive PEGASYS (Pegylated Interferon Alfa-2a) or Hydroxyurea (also known as Hydroxycarbamide). The treatment assigned will be chosen by chance.High Risk Polycythemia Vera or High Risk Essential ThrombocythemiaMedDRA version: 14.1Level: PTClassification code 10036057Term: Polycythaemia veraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019501-41-SECONSORZIO MARIO NEGRI SUD612
进行中（未招募）
1 期
Trial to compare the responses in two strata of patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia. Each patient will receive PEGASYS (Pegylated Interferon Alfa-2a) or Hydroxyurea (also known as Hydroxycarbamide). The treatment assigned will be chosen by chance.High Risk Polycythemia Vera or High Risk Essential ThrombocythemiaMedDRA version: 17.0Level: PTClassification code 10036057Term: Polycythaemia veraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019501-41-DEMyeloproliferative Disease Research Consortium (MPD-RC)612
进行中（未招募）
1 期
A randomized study comparing two drugs: hydroxyurea and Pegylated Interferon Alfa-2a, in an open label clinical trial in two independent diseases: (1) high risk polycythaemia vera and (2) high risk essential thrombocythaemia.The myeloproliferative disorders essential thrombocythaemia (ET) and polycythaemia vera (PV).MedDRA version: 14.1Level: LLTClassification code 10043550Term: ThrombocythemiaSystem Organ Class: 100000004851MedDRA version: 14.1Level: LLTClassification code 10036058Term: PolycythemiaSystem Organ Class: 100000004851EUCTR2010-019501-41-GBConsorzio Mario Negri Sud612
进行中（未招募）
不适用
Trial to compare the responses in two strata of patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia. Each patient will receive PEGASYS (Pegylated Interferon Alfa-2a) or Hydroxyurea (also known as Hydroxycarbamide). The treatment assigned will be chosen by chance.High Risk Polycythemia Vera or High Risk Essential ThrombocythemiaMedDRA version: 14.1Level: PTClassification code 10036057Term: Polycythaemia veraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019501-41-ITCONSORZIO MARIO NEGRI SUD612
未知
3 期
A study of peginterferon alfa-2a in combination with ribavirin in patients with chronic Hepatitis C.Chronic hepatitis CJPRN-jRCT2080220023Chugai Pharmaceutical Co., Ltd.